Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb : A case report
© 2023 The Authors..
Lung cancer stands as a leading cause of mortality in China, with EGFR mutations frequently identified as pivotal driver genes. Osimertinib, a tyrosine kinase inhibitor targeting EGFR mutations, is typically employed as a first-line treatment for EGFR-sensitive mutations; nevertheless, resistance can emerge. In this case report, we present the case of a 53-year-old non-smoking male diagnosed with stage IV lung adenocarcinoma bearing an EGFR exon 19 deletion. This patient eventually developed resistance to both Erlotinib and Osimertinib after 28 months of treatment. Subsequent genetic testing uncovered the emergence of new MET exon 14 skipping and MET fusion, coexisting with the initial EGFR exon 19 deletion. In light of this complex molecular profile, the patient was administered a combination therapy consisting of Osimertinib and Capmatinib. This novel approach yielded a partial response, and notably, the patient experienced a progression-free survival exceeding 7 months. Vigilant monitoring of the patient's progress revealed the disappearance of the MET exon 14 skipping and a notable improvement in the patient's symptoms. This case report underscores the potential efficacy of Osimertinib and Capmatinib combination therapy as a viable treatment strategy for patients harboring EGFR-mutated lung cancer who develop resistance to first-line EGFR inhibitors due to MET activation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Heliyon - 9(2023), 11 vom: 01. Nov., Seite e22515 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Xiang, Siqi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Capmatinib |
---|
Anmerkungen: |
Date Revised 11.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.heliyon.2023.e22515 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM365656828 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM365656828 | ||
003 | DE-627 | ||
005 | 20231229123327.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.heliyon.2023.e22515 |2 doi | |
028 | 5 | 2 | |a pubmed24n1227.xml |
035 | |a (DE-627)NLM365656828 | ||
035 | |a (NLM)38074875 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Xiang, Siqi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb |b A case report |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 11.12.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2023 The Authors. | ||
520 | |a Lung cancer stands as a leading cause of mortality in China, with EGFR mutations frequently identified as pivotal driver genes. Osimertinib, a tyrosine kinase inhibitor targeting EGFR mutations, is typically employed as a first-line treatment for EGFR-sensitive mutations; nevertheless, resistance can emerge. In this case report, we present the case of a 53-year-old non-smoking male diagnosed with stage IV lung adenocarcinoma bearing an EGFR exon 19 deletion. This patient eventually developed resistance to both Erlotinib and Osimertinib after 28 months of treatment. Subsequent genetic testing uncovered the emergence of new MET exon 14 skipping and MET fusion, coexisting with the initial EGFR exon 19 deletion. In light of this complex molecular profile, the patient was administered a combination therapy consisting of Osimertinib and Capmatinib. This novel approach yielded a partial response, and notably, the patient experienced a progression-free survival exceeding 7 months. Vigilant monitoring of the patient's progress revealed the disappearance of the MET exon 14 skipping and a notable improvement in the patient's symptoms. This case report underscores the potential efficacy of Osimertinib and Capmatinib combination therapy as a viable treatment strategy for patients harboring EGFR-mutated lung cancer who develop resistance to first-line EGFR inhibitors due to MET activation | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Capmatinib | |
650 | 4 | |a EGFR | |
650 | 4 | |a MET exon 14 skipping | |
650 | 4 | |a MET fusion | |
650 | 4 | |a NSCLC | |
650 | 4 | |a Osimertinib | |
650 | 4 | |a Resistance mechanism | |
700 | 1 | |a Zeng, Liang |e verfasserin |4 aut | |
700 | 1 | |a Xiang, Mingjun |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Yongchang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Heliyon |d 2015 |g 9(2023), 11 vom: 01. Nov., Seite e22515 |w (DE-627)NLM255913095 |x 2405-8440 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2023 |g number:11 |g day:01 |g month:11 |g pages:e22515 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.heliyon.2023.e22515 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2023 |e 11 |b 01 |c 11 |h e22515 |